Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel 1,2,4-oxadiazole derivatives as selective butyrylcholinesterase inhibitors: Design, synthesis and biological evaluation.
Maryam Nazari, Elham Rezaee, Roshanak Hariri, et al.
EXCLI journal (2021) Vol. 20, pp. 907-921
Closed Access | Times Cited: 8

Showing 8 citing articles:

Pharmacological significance of nitrogen-containing five and six-membered heterocyclic scaffolds as potent cholinesterase inhibitors for drug discovery
Rami J. Obaid, Ehsan Ullah Mughal, Nafeesa Naeem, et al.
Process Biochemistry (2022) Vol. 120, pp. 250-259
Closed Access | Times Cited: 78
Design, synthesis and in vitro biological activities of coumarin linked 1,3,4-oxadiazole hybrids as potential multi-target directed anti-Alzheimer agents
Namy George, Bushra Al Sabahi, Majed AbuKhader, et al.
Journal of King Saud University - Science (2022) Vol. 34, Iss. 4, pp. 101977-101977
Open Access | Times Cited: 29
Design, synthesis, and biological evaluation of 1,2,4-oxadiazole-based derivatives as multitarget anti-Alzheimer agents
Mohammed Salah Ayoup, Mohamed Reda Barakat, Hamida Abdel‐Hamid, et al.
RSC Medicinal Chemistry (2024) Vol. 15, Iss. 6, pp. 2080-2097
Closed Access | Times Cited: 6
Heterocyclic Compounds as Dipeptidyl Peptidase-IV Inhibitors with Special Emphasis on Oxadiazoles as Potent Anti-Diabetic Agents
Badrud Duza Mohammad, Mirza Shahed Baig, Neeraj Bhandari, et al.
Molecules (2022) Vol. 27, Iss. 18, pp. 6001-6001
Open Access | Times Cited: 20
Chromenone: An emerging scaffold in anti-Alzheimer drug discovery
Uma Agarwal, Saroj Verma, Rajiv Kumar Tonk
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 111, pp. 129912-129912
Closed Access | Times Cited: 1
Recent Advancements in the Treatment of Alzheimer’s Disease: A Multitarget-directed Ligand Approach
Sumit Kumar, Amol T. Mahajan, Ramesh Ambatwar, et al.
Current Medicinal Chemistry (2023) Vol. 31, Iss. 37, pp. 6032-6062
Closed Access | Times Cited: 2
In-silico Molecular Docking Studies of Methyl Oxadiazole Hybrids Inhibiting Acetylcholinesterase for Alzheimer’s Disease Treatment
M Magesh, R. Gandhimathi
International Journal of Pharmaceutical Quality Assurance (2024) Vol. 15, Iss. 01, pp. 403-413
Open Access
In silico identification of novel heterocyclic compounds combats Alzheimer’s disease through inhibition of butyrylcholinesterase enzymatic activity
Hai Duc Nguyen
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 20, pp. 10890-10910
Closed Access | Times Cited: 1
Page 1

Scroll to top